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A TASTE OF HOME FOR THE HOLIDAYS: PROVIDING A TRADITIONAL
HOLIDAY DINNER FOR INPATIENT STEM CELL TRANSPLANT PATIENTS
AND CAREGIVERS
Doyle, K. MD Anderson Cancer Center, Houston, TX
Background: Patients and caregivers undergoing hematopoietic
stem cell transplants (SCT) commit to long hospital stays, often last-
ing up to four weeks. During this time, patients, familymembers, and
caregivers are temporarily located in places other than their home
towns. This presents emotional, financial, and family challenges.
Holidays away from home are especially difficult, and may contrib-
ute to anxiety and depression.
Intervention: To support patients and caregivers who are away
from home and family, a large, comprehensive cancer center holds
a dinner between the major holidays of Thanksgiving and Christ-
mas. This has been a yearly event for the past 15 years. The din-
ner is planned, funded, and produced by the staff and aims to
provide a sense of home. The staff hosts fundraisers throughout
the year to support the dinner. The menu consists of both catered
and home-cooked dishes, mimicking the traditional American
holiday dinner. Staff members volunteer to set up, serve, and
clean up.
Evaluation: The holiday dinner has been beneficial for all who are
involved. Staff participation boosts morale and team spirit. Patients
and their caregivers are able to celebrate the holidays with their tem-
porary staff and fellow patient and caregiver family. The expressions
of heartfelt thanks and gratitude for the thoughtful efforts of the
staff, are almost overwhelming. Specific patient, caregiver, and staff
feedback will be shared.
Discussion: The annual holiday dinner serves as a means to pro-
vide patients and caregivers a dedicated time for social interaction
and a sense of normalcy during the stem cell transplant process.
Benefits of the holiday dinner for both patients and staff have as-
sured that the tradition has been passed on for 15 years, and will
continue.318
CYTOMEGALOVIRUS INFECTION OCCURRING BEFORE ENGRAFTMENT IN
RECIPIENTS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANS-
PLANTATION FROM ALTERNATIVE DONORS
Cozzi, J., Basso, A., Saslavsky, J., Saslavsky, M., Prone, L. CETRAMOR
BMT-Unit, Rosario, Santa Fe, Argentina
Background: Cytomegalovirus (CMV) remains an important infec-
tious cause of morbidity and mortality among allogeneic Haema-
topoietic Stem Cell Transplantation (aHSCT) recipients (r).
CMV-seropositive r of transplants from alternative (A) donors are
at higher risk for very early onset of CMV infection (I) and disease
(D). Quantitative (q) polymerase chain reaction (PCR) assay for
CMVDNA in whole (W) blood (B) samples (S) is useful in identifing
patients (p) at risk for CMV-D before engraftment (E).
Methods: From 10/2008 to 10/2011 21 p who underwent A donor
aHSCT were studied. p in this cohort were tested bi-weekly by
qPCR assay for CMV DNA in WBS with a threshold for preemp-
tive (P) therapy (Th) at 500 copies (c)/ml (limit of detection). P Th
pre-E was started on IV foscarnet (F) 60 mg/Kg twice daily 14 days
as induction Th, followed by maintenance Th with 90 mg/Kg once
daily dosing until routine surveillance testing was negative. Age,
median (range) 28 (3-54) years. Male sex: 12 p (57%). Underlying
diseases: AML (6 p), ALL (6 p), CML (2 p), SAA (2 p), Inherited
Disorders of Metabolism (2 p), CMML (1 p), NHL (1 p), HL (1
p). D state at time of transplant: Refractory D: 12 p (57%),
CR.2nd: 5 p (24%). Conditioning Regimen: Reduced Intensity:
13 p (62%), Myeloablative: 8 p (38%). TBI (5 p)/TLI (8 p): 13p (62%). ATG (8 p)/CAMPATH-1H (3 p): 11 p (52%). Donors
Matched Unrelated (U): 5 p, Mismatched (MM) U: 6 p, MM
Related: 5 p, MM Umbilical Cord Blood (UCB): 5 p. Graft source:
peripheral blood stem cells: 16 p (76%), UCB: 5 p (24%). Graft-
versus-host disease (GVHD) prophylaxis: Cyclosporine + Myco-
phenolate Mofetil: 12 p (57%). Hyperacute GVHD 2 p (9,5%)
requiring high-doses corticosteroids. Acyclovir was given to Herpes
Simplex Virus seropositive r from the start of conditioning. CMV
serostatus: D+/R+: 12 p (57%), D-/R+: 9 p (43%). E was defined as
3 consecutive days with an absolute neutrophil (N) count .500
cells/uL.
Results: The median (range) time to N E was 19 (9-41) days. 8 p
(38%) developed CMV reactivation (R) prior to E. The median
(range) time to CMV-R was 12 (3-26) days. The median (range)
initial viral load in those p who developed CMV-R was 3.000
(500-10.000) c/ml. IV F was instituted as P antiviral Th in all p
who developed CMV-I pre-E. 1 p (4,8%) developed CMV-D (en-
cephalitis). None of these p died of CMV-D. F Th was not discon-
tinued in any p because of adverse effects.
Conclusion: Our study shows that a P treatment strategy based on
qPCR tests surveillance is safe and effective for treating CMV-I
ocurring before E in recipients of aHSCT from A donors.319
TRANSFUSION OF RED CELLS IN HEMATOPOIETIC STEM CELL TRANS-
PLANTATION: THE TRIST STUDY
Tay, J.1,2, Tinmouth, A.2, Fergusson, D.2, Allan, D.1 1Ottawa Hospital,
Ottawa, ON, Canada; 2University of Ottawa and Clinical Epidemiology
Program, Ottawa, ON, Canada
Background: Insight regarding transfusion practices inHematopoi-
etic Stem cell Transplantation (HSCT) are lacking, and the impact
of red blood cell (RBC) transfusion on outcomes following HSCT
are not well appreciated. A randomized study of transfusion is
required to gain insight on best transfusion practices in this
population.
Methods: In preparation for our trial, all adult transplant centres
associated with the Canadian Blood and Marrow Transplant Group
(CBMTG)(n 5 15) were asked to respond to a survey regarding
transfusion thresholds. Fourteen centres routinely transfuse 2 units
of RBCs when the hemoglobin\80 g/L and/or in response to pa-
tient specific indications while one centre transfuses RBCs when
the hemoglobin \70 g/L. The rationale for the near universal
adoption of red cell transfusion trigger of 80 g/L remains unclear.
Our centre has historically adopted a red cell transfusion trigger of
80 g/L and we conducted an audit of our practices for the year
2009. Despite our established trigger of 80 g/L, RBC transfusions
above this trigger occurred in 50% of all transplant patients ever
requiring red cells within the 1st 100 days of the transplant.
Further, 20% of all RBC transfusions occurred above the stated
trigger.
Results: Two of 5 invited CBMTG centres declined participation
for logistical reasons. In 3 centres, 100 patients undergoing HSCT
will be randomized to either a restrictive (target hemoglobin of 70-
90g/L) or liberal (target hemoglobin of 90-110g/L) RBC transfu-
sion strategy, based on daily hemoglobin values up to 100 days
post-transplant. The primary goal is to demonstrate study feasibil-
ity while collecting clinical outcomes on 1) Transfusion Require-
ments, 2) Transplant Related Mortality, 3) Maximum grade of
acute Graft versus Host Disease, 4) Veno-occlusive Disease, 5) Se-
rious Infections, 6) Bearman Toxicity Score, 7) Bleeding, 8) Qual-
ity of Life, 9) Number of Hospitalizations and Intensive Care Unit
admissions. At the time of writing, 25 patients have been followed
for 28 days post HSCT, with our 1st Data Safety Monitoring
Board review pending.
Conclusion: No CBMTG centre has clearly embraced a liberal
transfusion strategy and only 1 centre has embarked on a more re-
strictive strategy. This indicates some relative uncertainty with re-
gards to the benefits and harms of RBC transfusion in the HSCT
population. Upon completion, this pilot trial will provide
